Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice

Immunotherapy

Volumn 3, Issue 6, 2011, Pages 735-746

  Karan, Dev ^a,b   Dubey, Seema ^b   Van Veldhuizen, Peter ^a,b   Holzbeierlein, Jeffrey M ^a,b   Tawfik, Ossama ^b   Thrasher, J Brantley ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

adenovirus; immunotherapy; prostate cancer; tumor vaccine

Indexed keywords

ADENOVIRUS VECTOR; BETA GALACTOSIDASE; COMPLEMENTARY DNA; GAMMA INTERFERON; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; TUMOR VACCINE;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY TEST; DENDRITIC CELL; EFFECTOR CELL; FUSION GENE; GENE AMPLIFICATION; IMMUNIZATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TARGET CELL; TUMOR CELL LINE; TUMOR GROWTH; TUMOR IMMUNITY;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; GPI-LINKED PROTEINS; HUMANS; IMMUNOTHERAPY, ACTIVE; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM PROTEINS; OVALBUMIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINES, DNA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959193683     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.11.59     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J et al.: Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
2. Drake CG: Immunotherapy for prostate cancer: an emerging treatment modality. Urol. Clin. North Am. 37, 121-129 (2010).
3. Harzstark AL, Small EJ: Immunotherapeutics in development for prostate cancer. Oncologist 14, 391-398 (2009).
4. Elzey BD, Siemens DR, Ratliff TL et al.: Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer 94, 842-849 (2001). (Pubitemid 33032833)
5. Kaufman HL, Wang W, Manola J et al.: Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 22, 2122-2132 (2004). (Pubitemid 41095145)
6. Lubaroff DM, Konety BR, Link B et al.: Phase I clinical trial of an adenovirus/ prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin. Cancer Res. 15, 7375-7380 (2009).
7. Meidenbauer N, Harris DT, Spitler LE et al.: Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 43, 88-100 (2000). (Pubitemid 30220611)
8. Pavlenko M, Roos AK, Lundqvist A et al.: A Phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br. J. Cancer 91, 688-694 (2004). (Pubitemid 39141625)
9. Slovin SF, Ragupathi G, Musselli C et al.: Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with α-N-acetylgalactosamine-Oserine/threonine conjugate vaccine. J. Clin. Oncol. 21, 4292-4298 (2003). (Pubitemid 46621804)
10. Kantoff PW, Higano CS, Shore ND et al.: Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
11. Antonarakis ES, Heath EI, Walczak JR et al.: Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J. Clin. Oncol. 27, 4986-4993 (2009).
12. Kantoff PW, Schuetz TJ, Blumenstein BA et al.: Overall survival analysis of a Phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28, 1099-1105 (2010).
13. Eastham JA, Riedel E, Scardino PT et al.: Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA 289, 2695-2700 (2003). (Pubitemid 37430140)
14. Soletormos G, Semjonow A, Sibley PE et al.: Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin. Chem. 51, 1342-1351 (2005). (Pubitemid 41060864)
15. Reiter RE, Gu Z, Watabe T et al.: Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl Acad. Sci. USA 95, 1735-1740 (1998). (Pubitemid 28103463)
16. Zhigang Z, Wenlv S: Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Jpn J. Clin. Oncol. 34, 414-419 (2004). (Pubitemid 43115305)
17. Gu Z, Thomas G, Yamashiro J et al.: Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19, 1288-1296 (2000). (Pubitemid 30160621)
18. Raff AB, Gray A, Kast WM: Prostate stem cell antigen: a prospective therapeutic and diagnostic target. Cancer Lett. 277, 126-132 (2009).
19. Garcia-Hernandez Mde L, Gray A, Hubby B et al.: Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res. 68, 861-869 (2008). (Pubitemid 351206764)
20. Dannull J, Diener PA, Prikler L et al.: Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res. 60, 5522-5528 (2000).
21. + patients with hormone-refractory prostate cancer. Cancer Immunol. Immunother. 53, 479-489 (2004). (Pubitemid 38680254)
22. Anderson RD, Haskell RE, Xia H et al.: A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther. 7, 1034-1038 (2000). (Pubitemid 30398352)
23. Lubaroff DM, Karan D, Andrews MP et al.: Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine 24, 6155-6162 (2006). (Pubitemid 44202567)
24. Karan D, Krieg AM, Lubaroff DM: Paradoxical enhancement of CD8 T celldependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int. J. Cancer 121, 1520-1528 (2007). (Pubitemid 47328711)
25. Pavlenko M, Leder C, Roos AK et al.: Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate 64, 50-59 (2005). (Pubitemid 40734738)
26. + tumors growth in mice. J. Gene Med. 9, 715-726 (2007). (Pubitemid 47288829)
27. Risk M, Corman JM: The role of immunotherapy in prostate cancer: an overview of current approaches in development. Rev. Urol. 11, 16-27 (2009).
28. Stavridi F, Karapanagiotou EM, Syrigos KN: Targeted therapeutic approaches for hormonerefractory prostate cancer. Cancer Treat. Rev. 36, 122-130 (2010).
29. Antonarakis ES, Drake CG: Current status of immunological therapies for prostate cancer. Curr. Opin. Urol. 20, 241-246 (2010).
30. Higano CS, Schellhammer PF, Small EJ et al.: Integrated data from 2 randomized, doubleblind, placebo-controlled, Phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115, 3670-3679 (2009).
31. Thomas-Kaskel AK, Waller CF, Schultze- Seemann W et al.: Immunotherapy with dendritic cells for prostate cancer. Int. J. Cancer 121, 467-473 (2007). (Pubitemid 46986477)
32. Waeckerle-Men Y, Uetz-von Allmen E, Fopp M et al.: Dendritic cell-based multiepitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol. Immunother. 55, 1524-1533 (2006). (Pubitemid 44327840)
33. Medin JA, Liang SB, Hou JW et al.: Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther. 12, 540-551 (2005). (Pubitemid 40686594)
34. Melief CJ, van der Burg SH: Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8, 351-360 (2008). (Pubitemid 351589701)
35. Robson NC, Hoves S, Maraskovsky E et al.: Presentation of tumour antigens by dendritic cells and challenges faced. Curr. Opin. Immunol. 22, 137-144 (2010).
36. Engell-Noerregaard L, Hansen TH, Andersen MH et al.: Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol. Immunother. 58, 1-14 (2009).
37. Kim S, Lee JB, Lee GK et al.: Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Prostate 69, 938-948 (2009).
38. Roos AK, Pavlenko M, Charo J et al.: Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. Prostate 62, 217-223 (2005). (Pubitemid 40129059)